SG11201601486TA - Heterocyclic compounds and methods of use - Google Patents

Heterocyclic compounds and methods of use

Info

Publication number
SG11201601486TA
SG11201601486TA SG11201601486TA SG11201601486TA SG11201601486TA SG 11201601486T A SG11201601486T A SG 11201601486TA SG 11201601486T A SG11201601486T A SG 11201601486TA SG 11201601486T A SG11201601486T A SG 11201601486TA SG 11201601486T A SG11201601486T A SG 11201601486TA
Authority
SG
Singapore
Prior art keywords
methods
heterocyclic compounds
heterocyclic
compounds
Prior art date
Application number
SG11201601486TA
Inventor
Sarvajit Chakravarty
Roopa Rai
Son Minh Pham
Brahmam Pujala
Ramniwas Jangir
Rambabu Guguloth
Vijay Kumar Sharma
Original Assignee
Sarvajit Chakravarty
Roopa Rai
Son Minh Pham
Brahmam Pujala
Ramniwas Jangir
Rambabu Guguloth
Vijay Kumar Sharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarvajit Chakravarty, Roopa Rai, Son Minh Pham, Brahmam Pujala, Ramniwas Jangir, Rambabu Guguloth, Vijay Kumar Sharma filed Critical Sarvajit Chakravarty
Publication of SG11201601486TA publication Critical patent/SG11201601486TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
SG11201601486TA 2013-08-28 2014-08-28 Heterocyclic compounds and methods of use SG11201601486TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2816MU2013 2013-08-28
IN3497MU2013 2013-11-04
PCT/US2014/053215 WO2015031650A1 (en) 2013-08-28 2014-08-28 Heterocyclic compounds and methods of use

Publications (1)

Publication Number Publication Date
SG11201601486TA true SG11201601486TA (en) 2016-03-30

Family

ID=52584081

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201601486TA SG11201601486TA (en) 2013-08-28 2014-08-28 Heterocyclic compounds and methods of use
SG10201806370QA SG10201806370QA (en) 2013-08-28 2014-08-28 Heterocyclic compounds and methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201806370QA SG10201806370QA (en) 2013-08-28 2014-08-28 Heterocyclic compounds and methods of use

Country Status (28)

Country Link
US (1) US9670172B2 (en)
EP (1) EP3038622B1 (en)
JP (2) JP2017506618A (en)
KR (1) KR20160067841A (en)
CN (1) CN106029072A (en)
AU (1) AU2014312245B2 (en)
CA (1) CA2922346A1 (en)
CR (1) CR20160136A (en)
DK (1) DK3038622T3 (en)
EC (1) ECSP16012582A (en)
ES (1) ES2676585T3 (en)
HR (1) HRP20181017T1 (en)
HU (1) HUE039624T2 (en)
IL (1) IL244268A0 (en)
LT (1) LT3038622T (en)
MX (1) MX2016002443A (en)
NO (1) NO20160470A1 (en)
PH (1) PH12016500382A1 (en)
PL (1) PL3038622T3 (en)
PT (1) PT3038622T (en)
RS (1) RS57338B1 (en)
RU (1) RU2016111138A (en)
SA (1) SA516370641B1 (en)
SG (2) SG11201601486TA (en)
SI (1) SI3038622T1 (en)
TR (1) TR201809185T4 (en)
UA (1) UA116675C2 (en)
WO (1) WO2015031650A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9873689B2 (en) 2014-11-07 2018-01-23 Fgh Biotech, Inc. Synthesis of fatostatin based polycyclic compounds
US10328064B2 (en) 2014-12-23 2019-06-25 Fgh Biotech, Inc. Compositions of fatostatin based heterocyclic compounds and uses thereof
EP3265088A1 (en) * 2015-03-04 2018-01-10 Medivation Technologies LLC Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance
WO2016141258A1 (en) 2015-03-04 2016-09-09 Medivation Technologies, Inc. Sterol regulatory element-binding proteins (srebps) inhibitors
CN105732355A (en) * 2016-04-07 2016-07-06 戊言医药科技(上海)有限公司 Preparation method of 1-(5-fluoro-2-iodophenyl)ethanone
ES2912921T3 (en) 2016-04-29 2022-05-30 Fgh Biotech Inc Disubstituted pyrazole compounds for the treatment of diseases
EP3510027B1 (en) * 2016-09-07 2022-11-02 FGH BioTech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
WO2019046316A1 (en) * 2017-08-28 2019-03-07 Acurastem Inc. Pikfyve kinase inhibitors
EP3746070A4 (en) * 2018-01-29 2021-09-01 Capulus Therapeutics, LLC Srebp inhibitors comprising a 6-membered central ring
WO2020132700A1 (en) 2018-12-21 2020-06-25 Fgh Biotech Inc. Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
WO2021154735A1 (en) * 2020-01-27 2021-08-05 Capulus Therapeutics, Llc Srebp inhibitors comprising a thiophene central ring
CN116041277A (en) * 2023-01-18 2023-05-02 中国药科大学 Phenyl and biphenyl substituted five-membered heterocyclic compound, preparation method, pharmaceutical composition and application thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3796764B2 (en) * 1995-01-25 2006-07-12 コニカミノルタホールディングス株式会社 Metal complex compound and optical recording medium using the compound
US6291514B1 (en) * 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
ATE223408T1 (en) 1998-02-09 2002-09-15 Dimensional Pharm Inc HETEROARYL-AMIDINES, METHYLAMIDINES AND -GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS
CA2337822A1 (en) * 1998-06-09 1999-12-16 The University Of Connecticut Inhibitors of the anandamide transporter as analgesic agents
US6444687B1 (en) * 1999-12-16 2002-09-03 Schering Corporation Substituted imidazole neuropeptide Y Y5 receptor antagonists
AR029686A1 (en) 2000-06-22 2003-07-10 Dow Agrosciences Llc COMPOUNDS OF 2- (3,5-DISPOSED-4-PIRIDIL) -4- (TIENYL, THIAZOLYL OR ARYLFENYL) -1,3-OXAZOLINE, COMPOSITIONS AND METHODS FOR THE CONTROL OF INSECTS OR ACAROS AND / OR PLANTS USING SUCH COMPOUNDS
BRPI0410348A (en) 2003-05-14 2006-05-30 Torreypines Therapeutics Inc compounds and uses thereof in amyloid-beta modulation
AU2006272978B2 (en) 2005-07-26 2012-06-07 Bial - Portela & Ca, S.A. Nitrocatechol derivatives as COMT inhibitors
WO2007021941A2 (en) 2005-08-16 2007-02-22 Icagen, Inc. Inhibitors of voltage-gated sodium channels
US8229106B2 (en) 2007-01-22 2012-07-24 D.S.P. Group, Ltd. Apparatus and methods for enhancement of speech
AU2008214095B2 (en) 2007-02-02 2014-07-10 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9212179B2 (en) 2007-02-02 2015-12-15 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
US20120040951A1 (en) * 2008-12-30 2012-02-16 Claudio Chuaqui Heteroaryl compounds useful as raf kinase inhibitors
US8242260B2 (en) * 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
CA2786424A1 (en) 2010-01-08 2011-07-14 Ruga Corporation Raf kinase inhibitors
WO2012084678A1 (en) 2010-12-23 2012-06-28 Syngenta Participations Ag Novel imidazoles useful as plant fungicides
GB201116017D0 (en) 2011-09-16 2011-10-26 Univ Surrey Bi-aromatic and tri-aromatic compounds as nadph oxidase inhibitors
EP2793880A4 (en) 2011-12-23 2015-06-24 Millennium Pharm Inc Heteroaryls and uses thereof
WO2014199164A1 (en) 2013-06-12 2014-12-18 Ampla Pharmaceuticals, Inc. Diaryl substituted heteroaromatic compounds
WO2014210389A1 (en) 2013-06-26 2014-12-31 Rett Syndrome Research Trust Rett syndrome and treatments therefore

Also Published As

Publication number Publication date
CR20160136A (en) 2016-08-04
EP3038622A1 (en) 2016-07-06
JP2017506618A (en) 2017-03-09
TR201809185T4 (en) 2018-07-23
ECSP16012582A (en) 2018-09-30
PH12016500382A1 (en) 2016-05-16
HRP20181017T1 (en) 2018-08-24
CA2922346A1 (en) 2015-03-05
ES2676585T3 (en) 2018-07-23
PL3038622T3 (en) 2018-09-28
EP3038622B1 (en) 2018-05-30
LT3038622T (en) 2018-07-25
CN106029072A (en) 2016-10-12
RS57338B1 (en) 2018-08-31
US9670172B2 (en) 2017-06-06
SI3038622T1 (en) 2018-08-31
RU2016111138A (en) 2017-10-04
PT3038622T (en) 2018-07-13
AU2014312245A1 (en) 2016-04-07
NO20160470A1 (en) 2016-03-18
JP2019089854A (en) 2019-06-13
US20150065519A1 (en) 2015-03-05
WO2015031650A1 (en) 2015-03-05
SG10201806370QA (en) 2018-08-30
SA516370641B1 (en) 2018-05-21
MX2016002443A (en) 2016-12-16
RU2016111138A3 (en) 2018-06-27
AU2014312245B2 (en) 2018-12-13
HUE039624T2 (en) 2019-01-28
EP3038622A4 (en) 2017-04-12
UA116675C2 (en) 2018-04-25
DK3038622T3 (en) 2018-07-16
KR20160067841A (en) 2016-06-14
IL244268A0 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
HRP20181392T1 (en) Heterocyclic compounds and uses thereof
HK1223351A1 (en) Heterocyclic compounds and uses thereof
ZA201602220B (en) Heterocyclic compounds and uses thereof
HK1217428A1 (en) Substituted benzoxazoles and methods of use thereof
SG11201600707QA (en) Substituted aminopyrimidine compounds and methods of use
HK1218512A1 (en) Heterocyclic compounds and their uses
IL244268A0 (en) Heterocyclic compounds and methods of use
EP2938341A4 (en) Heterocyclic compounds and methods of use thereof
PT3019477T (en) Heterocyclic compounds and methods of their use
HK1220363A1 (en) Heterocyclic compounds and their uses